Michael C Nicastri
Overview
Explore the profile of Michael C Nicastri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
492
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Laudadio G, Neigenfind P, Chebolu R, Blasczak V, Maddirala S, Palkowitz M, et al.
Org Lett
. 2024 Mar;
26(11):2276-2281.
PMID: 38467055
A simple protocol is outlined herein for rapid access to enantiopure unnatural amino acids (UAAs) from trivial glutamate and aspartate precursors. The method relies on Ag/Ni-electrocatalytic decarboxylative coupling and can...
2.
Laudadio G, Neigenfind P, Peter A, Rubel C, Emmanuel M, Oderinde M, et al.
Angew Chem Int Ed Engl
. 2024 Jan;
63(8):e202314617.
PMID: 38181042
There is a pressing need, particularly in the field of drug discovery, for general methods that will enable direct coupling of tertiary alkyl fragments to (hetero)aryl halides. Herein a uniquely...
3.
Sharma G, Ojha R, Noguera-Ortega E, Rebecca V, Attanasio J, Liu S, et al.
JCI Insight
. 2022 Oct;
7(20).
PMID: 36278493
No abstract available.
4.
Sharma G, Ojha R, Noguera-Ortega E, Rebecca V, Attanasio J, Liu S, et al.
JCI Insight
. 2020 Aug;
5(17).
PMID: 32780726
New strategies are needed to enhance the efficacy of anti-programmed cell death protein antibody (anti-PD-1 Ab) in cancer. Here, we report that inhibiting palmitoyl-protein thioesterase 1 (PPT1), a target of...
5.
Nicastri M, Lehnherr D, Lam Y, DiRocco D, Rovis T
J Am Chem Soc
. 2020 Jan;
142(2):987-998.
PMID: 31904228
Primary amines are an important structural motif in active pharmaceutical ingredients (APIs) and intermediates thereof, as well as members of ligand libraries for either biological or catalytic applications. Many chemical...
6.
Lehnherr D, Lam Y, Nicastri M, Liu J, Newman J, Regalado E, et al.
J Am Chem Soc
. 2019 Dec;
142(1):468-478.
PMID: 31849221
Accessing hindered amines, particularly primary amines α to a fully substituted carbon center, is synthetically challenging. We report an electrochemical method to access such hindered amines starting from benchtop-stable iminium...
7.
Rebecca V, Nicastri M, Fennelly C, Chude C, Barber-Rotenberg J, Ronghe A, et al.
Cancer Discov
. 2018 Nov;
9(2):220-229.
PMID: 30442709
Clinical trials repurposing lysosomotropic chloroquine (CQ) derivatives as autophagy inhibitors in cancer demonstrate encouraging results, but the underlying mechanism of action remains unknown. Here, we report a novel dimeric CQ...
8.
Baquero P, Dawson A, Mukhopadhyay A, Kuntz E, Mitchell R, Olivares O, et al.
Leukemia
. 2018 Sep;
33(4):981-994.
PMID: 30185934
In chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) treatment induces autophagy that promotes survival and TKI-resistance in leukemic stem cells (LSCs). In clinical studies hydroxychloroquine (HCQ), the only clinically...
9.
Dimeric quinacrines as chemical tools to identify PPT1, a new regulator of autophagy in cancer cells
Nicastri M, Rebecca V, Amaravadi R, Winkler J
Mol Cell Oncol
. 2018 Feb;
5(1):e1395504.
PMID: 29404393
DQ661 is a novel dimeric quinacrine that affects multiple lysosomal functions (autophagy and macropinocytosis) and mTORC1 (mechanistic target of rapamycin) activity by specifically targeting protein-palmitoyl thioesterase 1 (PPT1). DQ661 has...
10.
Piao S, Ojha R, Rebecca V, Samanta A, Ma X, McAfee Q, et al.
Autophagy
. 2017 Oct;
13(12):2056-2071.
PMID: 28981387
Lysosomal autophagy inhibitors (LAI) such as hydroxychloroquine (HCQ) have significant activity in a subset of cancer cell lines. LAIs are being evaluated in cancer clinical trials, but genetic determinants of...